Table 1

AuthorStudy designNumber of patients (n)DurationAgentResponseBleeding events

Janczak [19]
(2018)
Prospective, non-cirrhotic,
Atypical sites
Total
N=36
PVT
N= 16
Rivaroxaban
Apixaban
Recurrence rate
7.3 % (n=2)
(both had malignancy)
Minor
N=1 (3.6%)
Major
N=2 (7.2%)

Qi [20]
(2017)
Case report, cirrhotic, CPT not specifiedSMV, splenic vein, N=111 weeksRivaroxabanRecanalizationMelena and hematemesis

Nery [21]
(2017)
Case report
Non-cirrhotic
N=1>6mRivaroxaban 20 mg dailyComplete recanalization L branch,
partial recanalization right branch
None

De Gottardi [10]
(2016)
Retrospective, Both cirrhotic and non-cirrhotic,
Splanchnic
Total,
N= 94
PVT
N= 80
(Non cirrh-
N=38
Cirrh-
N=22)
Non-cirrhotic
13.1 m
cirrhotic
9.6 m
Rivaroxaban
Apixaban
Dabigatran
Not studiedCirrhosis:
Minor, n=7, Major, n=2
Non-cirrh:
Minor,
n= 4
Major, n=1

Hum [9]
(2016)
Retrospective,
Cirrhotic,
CPT A, B & C
All indications
Total,
N= 27
PVT
N=4
Rivaroxaban
15 mg bid
+/- 20 mg daily load,
Apixaban
5mg bid +/- 10mg bid load, No bridging
Recurrence rate 4%
(n=1)
Major
N=1 (4%)
Minor,
N=7

Yang [12]
(2016)
Case report, cirrhotic
CPT A
N=16 mRivaroxaban
15 mg bid x 3 wks, then 20 mg/d
Complete recanalizationNone

Intagliata [8]
(2015)
Retrospective, cirrhotic,
CPT A and B
Total
N= 20
PVT, N=12
10.6 mApixaban
Rivaroxaban
Not studiedMajor, n=1

Martinez [22]
(2014)
Case report,
Cirrhotics,
CPT A
N=16 mRivaroxaban
20 mg /d
Complete recanalizationNone

Lenz [11]
(2014)
Case report,
Cirrhotic
CPT A
N=15 mRivaroxaban 10 mg dailyComplete recanalizationNone

Pannach [23]
(2013)
Case report,
Non-cirrhotic
N=1>4 weeksRivaroxaban 20 mg dailyComplete recanalizationNone

CPT: Child Pugh Turcotte; Cirrh: cirrhosis.